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Peter D. Baade, PhD
IMPORTANCE Melanoma survivors are known to have a highly elevated risk of subsequent
primary melanomas.
OBJECTIVE To determine the relative risk of subsequent primary invasive melanomas
following a first primary invasive or in situ melanoma, with a focus on body site.
DESIGN, SETTING, AND PARTICIPANTS A retrospective cohort studywas conducted using
population-based administrative data for melanoma diagnoses collected by the Queensland
Cancer Registry, Queensland, Australia. Deidentified records of all cases of melanoma among
Queensland residents during the period 1982-2005were obtained and reviewed to
December 31, 2010. There were 39 668 eligible cases of first primary invasive melanoma and
22 845 cases of first primary in situ melanoma.
MAIN OUTCOMES ANDMEASURES Standardized incidence ratios (SIRs), a proxymeasure for
relative risk, were calculated by dividing the observed number of subsequent primary
invasive melanomas by the product of the strata-specific incidence rates that occurred in the
general population and the cumulative time at risk for the cohort. Synchronous subsequent
melanomas (diagnosed within 60 days of the first primary melanoma) were excluded.
Differences between SIRs were assessed using multivariate negative binomial regression
adjusted for sex, age group, time to second diagnosis, and body site and expressed in terms
of adjusted SIR ratios with corresponding 95% CIs.
RESULTS There were 5358 subsequent primary invasive melanomas diagnosed, resulting in
SIRs of 5.42 (95% CI, 5.23-5.61) and 4.59 (4.37-4.82) for persons with a first primary invasive
or in situ melanoma, respectively. The SIRs remained elevated throughout the follow-up
period. In general, subsequent primary invasive melanomas weremore likely to occur at the
same body site as the initial invasive or in situ melanoma. The largest relative risk was for
females with a first primary invasive melanoma on the head followed by a subsequent
primary invasive melanoma also on the head (SIR, 13.32; 95% CI, 10.28-16.98).
CONCLUSIONS AND RELEVANCE Melanoma survivors require ongoing surveillance, with
particular attention required for the body site of the initial lesion. Clinical practice guidelines
have recognized the importance of monitoring for people with invasive melanoma; the
results of the present study highlight the need for similar levels of supervision for those with a
diagnosis of in situ melanoma.
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M elanoma is a major public health issue in Australia,particularlywithin thenortheastern stateofQueens-land, which has the highest incidence rates of skin
cancer in theworld.1,2 Incidence rates for invasivemelanoma
in Queensland3 are more than 3 times those for the United
States and almost 6 times higher than the average through-
out Europe.4 In addition, the incidence of in situ melanoma
in Queensland has risenmarkedly since the 1980s, with rates
nowapproaching levels similar to thoseof invasivemelanoma.2
Comparable data on in situ melanomas are not routinely re-
ported for other countries, making benchmarking difficult.
Melanoma survivors are faced with an increased likeli-
hood of developing subsequent melanomas. Australians with
a first primary invasive melanoma are reported5,6 to have a 6-
to 7-fold higher risk of a second invasivemelanoma compared
with the general population. Although some authors7,8 have
foundthat theoccurrenceofsubsequentprimary invasivemela-
nomasare correlatedwith thebodysiteof theoriginal invasive
melanoma, toourknowledge, the relative risksbysitehavenot
been quantified. Furthermore, a small number of studies9,10
have shown an elevated risk of subsequent primary invasive
melanoma followingan initial primary in situmelanoma;how-
ever, information is lacking on the relative risks for different
combinationsofbodysites.We therefore conductedanexami-
nation ofwhether body site, sex, age group, and time since di-
agnosis influence theprobability of developing subsequent in-
vasive primary melanomas following a first invasive or in situ
primarymelanoma in a high-risk population.
Methods
Data Collection
Aretrospective cohort studywas conducted.Deidentified rec-
ords for cases of invasive and in situ melanoma were ob-
tained from the Queensland Cancer Registry. Notification of
all cancers diagnosed for Queensland residents, apart from
basal and squamous cell skin cancers, to the registry is re-
quired by law.3 Ethics board approval was not required be-
cause this study was conducted using deidentified data.
Available variables included sex, age at diagnosis, tumor
behavior, body site of the melanoma, date of diagnosis, and
date of death (when applicable). Body sitewas categorized as
head (including the face, ears, scalp, and neck), trunk, upper
extremities (including the shoulders), and lower extremities
(including the hips). Multiple primary melanomas for the
same person were linked through the use of unique study
numbers.
Thecohort includedallQueenslandresidentsaged15years
or older who received a diagnosis of a first primary invasive
or in situmelanoma(InternationalClassificationofDiseasesO-3
code C44 andmorphology codesM872-M879) between Janu-
ary 1, 1982, and December 31, 2005. Those who died within 2
months of diagnosis were excluded.
Patients’ records were reviewed until December 31, 2010,
potentially allowing aminimumof 5 years and amaximumof
29years to ascertain theoccurrenceof subsequentprimary in-
vasivemelanomas. Synchronous primary tumors (defined as
melanomas diagnosed within 2 months of the first primary
tumor11)were excludedbecause theyweremore likely tohave
beendiagnosedas a result of detectionbias.12Additionally,we
elected to exclude in situ second primary melanomas be-
cause of the risk of possible overdiagnosis.
If a person hadmore than 1 subsequent primary invasive
melanoma that occurredatdifferent body sites, thesewere in-
cluded in the study separately. However, only the first occur-
rence of a subsequent melanoma at a given body site was re-
tained for an individual person, and with evaluation of the
body as a whole, only the next primary invasive melanoma
(irrespective of body site) following the indexmelanomawas
considered.
Statistical Analysis
Standardized incidence ratios (SIRs) were used to approxi-
mate the relative risk of amelanoma survivor receiving a sub-
sequentprimary invasivemelanomadiagnosis comparedwith
a person in the general population ofQueensland. The SIR es-
timateswere calculatedusing a 3-step process. First, the time
at risk foreacheligiblememberof thestudywasmeasuredfrom
2months after diagnosis until the end of 2010, date of death,
ordateofdiagnosisofasubsequent invasivemelanoma,which-
ever came first. Second, the expected number of subsequent
primary invasive melanomas was calculated from the prod-
uct of the person-years at risk and the incidence rate experi-
enced by the Queensland population matched by sex, age
group, year of diagnosis, and body site (when relevant). Fi-
nally, the observed number of cases was divided by the ex-
pectednumber, andcorresponding95%CIswerederivedusing
a Poisson distribution.13
The degree and significance of differences between SIRs
was then formally tested using negative binomial regression.
Models were fitted with the observed number of subsequent
primary invasive melanomas as the dependent variable, off-
set by the log of the expected value. Sex, age group, time to
second diagnosis, and body site were included in each of the
models as confounding variables. The resultant adjusted SIR
ratioswere considered statistically significant atP < .05 for the
individual category comparedwith the reference category, as
well as for the overall effect of that variable. The above analy-
ses were stratified by the behavior of the first primary mela-
noma (invasive or in situ), as well as by sex, age at first diag-
nosis, time to second diagnosis, and site of the subsequent
tumor.
Results
Between January 1, 1982, and December 31, 2005, a total of
39 668 eligible cases of first primary invasive melanoma and
22 845firstprimary insitumelanomaswere identified.Theme-
dian follow-up times, excluding the first 2monthsafter the ini-
tialdiagnosis,were9.7years (interquartile range, 5.7-15.5years)
and 9.4 years (interquartile range, 6.3-14.2 years), respec-
tively. A total of 5358 subsequent primary invasive melano-
mas diagnosed in 4733 people were included in the study, of
which 3520melanomas (65.7%) occurred following a first pri-
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mary invasive melanoma and the remaining 1838 tumors
(34.3%) following a first primary in situ melanoma. Of those
with a subsequently diagnosed primary invasive melanoma,
4184 people (88.4%) had only 1 subsequent melanoma, 482
people (10.2%)had subsequentmelanomasat 2different body
sites, 58 individuals (1.2%) had subsequent melanomas on 3
different sites, and 9 people (0.2%) had a subsequent mela-
noma on each of the 4 broad body sites. In regard to thick-
ness, 25.0% and 28.6% of subsequent primary invasivemela-
nomas following a first in situ or invasive melanoma,
respectively, were more than 1 mm thick at diagnosis.
Other details of the study cohort are reported in Table 1.
Themostnotable contrastsbetween first primary invasiveand
in situ melanomas were that a higher proportion of invasive
tumorswasdiagnosed inpatientsyounger than50years (38.7%
vs 30.9%; P < .001) and that in situmelanomaswere farmore
likely to occur on the head than were invasive melanomas
(30.3% vs 15.1%; P < .001).
Although a significant difference was found in the distri-
bution of the time to diagnosis of a subsequent primary inva-
sive melanoma depending on whether the original mela-
nomawas invasive or in situ (P = .007), there was no obvious
pattern seen in thedata (Table 1). Excluding cases inwhich the
site was not reported, there was no evidence of a difference
inbodysiteof subsequentprimary invasivemelanomasby the
behavior of the first melanoma (P = .83).
Relative Risk of Subsequent Primary InvasiveMelanomas
Peoplewith a first primary invasivemelanomawere 5.4 times
more likely to develop a subsequently diagnosed primary in-
vasivemelanomaat any site comparedwith the general popu-
lation (SIR, 5.42; 95% CI, 5.23-5.61). The risk was 4.6 times
higher for those with an in situ first primary melanoma (SIR,
4.59; 95% CI, 4.37-4.82).
Site of First PrimaryMelanoma
The body site of the first primary invasive melanoma had no
effect (P = .27) on the overall relative risk of a subsequent in-
vasiveprimarymelanoma (Table 2). Therewas,however, a sig-
nificant difference (P = .007) by the body site of a first pri-
mary in situ melanoma; people who had an initial in situ
melanomaonbodysitesother thantheirheadhadahigher rela-
tive risk of a subsequentprimary invasivemelanoma, particu-
larly when the original lesion occurred on the lower extremi-
ties (adjusted SIR ratio, 1.34; 95% CI, 1.14-1.57).
Sex
Females with a first primary invasive melanoma on the head
were relatively more likely (adjusted SIR ratio, 1.35; 95% CI,
1.08-1.69) to develop a subsequently diagnosedprimary inva-
sivemelanomacomparedwithmales (Table 3). In contrast, fe-
maleshada less-elevated relative risk (adjustedSIR ratio,0.84;
95% CI, 0.71-0.98) of a subsequent primary invasive mela-
nomathanmales if their initial invasive lesionwasonthe lower
extremities. No significant differences by sexwere found fol-
lowing a first primary in situ melanoma (Table 4).
Age at First Diagnosis
Variation by age in the relative risk of a subsequent invasive
melanomawas found following a first primary invasivemela-
noma, but not for a first primary in situ melanoma (Table 2).
Further analysis bybody site showed that theeffect of agewas
Table 1. Characteristics of the Study Cohort
Characteristic
First Primary
Invasive Melanoma,
No. (%) of Patients
(n = 39 668)
Subsequent Primary
Invasive Melanomas,
No. (%) of
Melanomas
(n = 3520)a
First Primary In Situ
Melanoma,
No. (%) of Patients
(n = 22 845)
Subsequent Primary
Invasive Melanomas,
No. (%) of
Melanomas
(n = 1838)a
Sex
Male 22 128 (55.8) 2374 (67.4) 12 426 (54.4) 1221 (66.4)
Female 17 540 (44.2) 1146 (32.6) 10 419 (45.6) 617 (33.6)
Age at diagnosis, y
15-49 15 357 (38.7) 570 (16.2) 7061 (30.9) 196 (10.7)
50-64 11 152 (28.1) 912 (25.9) 7287 (31.9) 450 (24.5)
≥65 13 159 (33.2) 2038 (57.9) 8497 (37.2) 1192 (64.9)
Time to second
diagnosis
2 mo to <1 y NA 325 (9.2) NA 144 (7.8)
1 y to <5 y NA 1081 (30.7) NA 574 (31.2)
5 y to <10 y NA 994 (28.2) NA 589 (32.0)
≥10 y NA 1120 (31.8) NA 531 (28.9)
Site of melanoma
Head 5997 (15.1) 690 (19.6) 6928 (30.3) 353 (19.2)
Trunk 13 367 (33.7) 1195 (33.9) 6417 (28.1) 604 (32.9)
Upper extremities 9218 (23.2) 933 (26.5) 5498 (24.1) 470 (25.6)
Lower extremities 8682 (21.9) 661 (18.8) 3476 (15.2) 312 (17.0)
Not specified 2404 (6.1) 41 (1.2) 526 (2.3) 99 (5.4)
Abbreviation: NA, not applicable.
a Numbers of subsequent primary
invasive melanomasmay represent
more than 1 per person.
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mostprominentwhen the firstprimary invasivemelanomaoc-
curred on the trunk (Table 3). Within that subgroup, persons
aged 15 to 49 years had an adjusted SIR ratio of 1.26 (95% CI,
1.08-1.46) compared with those 65 years or older.
Time Between Diagnosis
Despite the SIRs remaining elevated for all periods to the end
of follow-up, the relative risk of a subsequent primary inva-
sivemelanomawasusuallyhighest in the first year than itwas
1 or more years after the initial diagnosis of a primary inva-
sive melanoma (Tables 2 and 3). Compared with 10 or more
years after diagnosis, the adjusted SIR ratios within 1 year of
the original diagnosis were significant for first primary inva-
sivemelanomas that occurred on the head (1.61; 95%CI, 1.14-
2.28), trunk (1.55; 95%CI, 1.26-1.92), orupper extremities (1.64;
95% CI, 1.27-2.12). Although the SIRs also tended to be higher
in the first year after diagnosis among the in situ cohort, there
was no clear pattern in the relative risks by time between di-
agnoses following a first primary in situ melanoma.
Site of Subsequent Primary InvasiveMelanomas
The body site at greatest relative risk for a subsequent pri-
mary invasive melanoma was typically the same as the site
of the first primary invasive or in situ melanoma (Tables 3
and 4 and Figure). This relationship was especially distinct
following a first primary melanoma on the head. In particu-
lar, females with a first primary invasive melanoma on the
head were 13 times more likely (SIR, 13.32; 95% CI, 10.28-
16.98) to develop a subsequently diagnosed primary inva-
sive melanoma on the head compared with the general
population (Figure). A strong association was also found fol-
lowing a first primary invasive melanoma on the lower
extremities, with the relative risk of a subsequent primary
invasive melanoma occurring on the lower extremities
being significantly higher (P < .001) than for any other
body site. However, there was no significant difference
(P = .41) observed in subsequent relative risk by body site
for persons with a first primary in situ melanoma on the
lower extremities.
Table 2. SIRs and Adj SIR Ratios for Subsequent Primary InvasiveMelanomas Following a First Primary Invasive or In SituMelanoma, Queensland,
1982-2010
Characteristica
First Primary Melanoma
Invasive In Situ
Obs SIR Adj SIR Ratio (95% CI) Obs SIR Adj SIR Ratio (95% CI)
Site of first primary melanoma P = .27 P = .007
Head 465 5.21 1 [Reference] 483 3.99 1 [Reference]
Trunk 1096 5.52 1.07 (0.95-1.22) 473 4.80 1.22 (1.06-1.40)
Upper extremities 739 5.38 1.04 (0.91-1.18) 392 4.83 1.18 (1.02-1.36)
Lower extremities 654 5.64 1.07 (0.94-1.22) 239 5.37 1.34 (1.14-1.57)
Not specified 143 4.68 0.90 (0.74-1.08) 49 4.44 1.21 (0.92-1.60)
Sex P = .68 P = .11
Male 2057 5.43 1 [Reference] 1067 4.44 1 [Reference]
Female 1040 5.39 0.98 (0.90-1.07) 569 4.90 1.10 (0.98-1.23)
Age at first diagnosis, y P = .007 P = .52
15-49 911 5.66 1.18 (1.06-1.31) 348 4.99 1.08 (0.94-1.25)
50-64 1024 5.44 1.10 (1.00-1.22) 563 4.57 1.02 (0.90-1.14)
≥65 1162 5.23 1 [Reference] 725 4.43 1 [Reference]
Time between diagnoses P < .001 P = .39
2 mo to <1 y 315 7.71 1.47 (1.28-1.69) 142 5.53 1.14 (0.94-1.39)
1 y to <5 y 1008 5.63 1.10 (0.99-1.22) 545 4.50 0.96 (0.84-1.10)
5 y to <10 y 877 5.21 1.02 (0.92-1.13) 511 4.55 1.02 (0.90-1.17)
≥10 y 897 4.89 1 [Reference] 438 4.50 1 [Reference]
Site of subsequent primary invasive
melanomab
P < .001 P = .02
Head 690 5.48 1 [Reference] 353 4.31 1 [Reference]
Trunk 1195 6.01 1.03 (0.92-1.16) 604 4.99 1.16 (1.00-1.35)
Upper extremities 933 6.02 1.06 (0.94-1.19) 470 4.84 1.10 (0.95-1.29)
Lower extremities 661 5.43 0.94 (0.83-1.07) 312 4.21 0.94 (0.79-1.11)
Not specified 41 1.01 0.18 (0.13-0.24) 99 3.91 0.90 (0.71-1.14)
Abbreviations: Adj, adjusted; Obs, observed; SIR, standardized incidence ratio.
a P values represent the statistical significance of the overall effect for the
variable. Adjusted SIR ratios shown in boldface type are statistically significant
(P < .05).
bNumbers by site of subsequent primary invasive melanomasmay represent
more than 1 per person.
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The relative risk of subsequent primary invasivemelano-
masvaried across theother secondary sites, dependingon the
person’s sex and the site and behavior of the initial lesion, al-
though all combinations resulted in a risk of melanoma that
was significantlyhigher than thatof thegeneralpopulation (ie,
SIR >1; Figure). For example, males with a first primary inva-
sive melanoma on the upper extremities had an equally high
relative risk of a subsequently diagnosed primary invasive
melanomaon theupper or lower extremities (Figure), but less
so for the head (adjusted SIR ratio, 0.63; 95%CI, 0.49-0.81) or
trunk (adjusted SIR ratio, 0.73; 0.59-0.90). In contrast, among
females with an initial invasive melanoma on the upper ex-
tremities, there was an equally high relative risk of a subse-
quent primary invasive melanoma on the head, trunk, or
upper extremities, but a less-elevated risk for the lower ex-
tremities (adjusted SIR ratio, 0.71; 95% CI, 0.53-0.96).
Discussion
The present investigation demonstrated that all people with
melanoma, whether it be an invasive or in situ lesion, are at a
significantly and substantially increased risk of a subsequent
primary invasivemelanoma comparedwith the age- and sex-
matched general population. Although therewas somevaria-
tion in the size of the relative risk by key characteristics, such
as sex, age at first diagnosis, time after initial diagnosis, the
body site of both the first and subsequent melanomas, and
whether the first primary melanoma was invasive or in situ,
a highly increased risk was maintained across all of these
subgroups.
We found that people with melanoma tended to have
the greatest relative risk of subsequent primary invasive
Table 3. SIRs and Adj SIR Ratios for Subsequent Primary InvasiveMelanomas by Site of First Primary InvasiveMelanoma, Queensland, 1982-2010
Characteristica
Site of First Primary Invasive Melanoma
Head Trunk Upper Extremities Lower Extremities Not Specified
Obs SIR
Adj SIR
Ratio
(95% CI) Obs SIR
Adj SIR
Ratio
(95% CI) Obs SIR
Adj SIR
Ratio
(95% CI) Obs SIR
Adj SIR
Ratio
(95% CI) Obs SIR
Adj SIR
Ratio
(95% CI)
Sex P = .009 P = .44 P = .20 P = .03 P = .27
Male 316 4.83 1
[Reference]
880 5.60 1
[Reference]
465 5.53 1
[Reference]
307 6.01 1
[Reference]
89 4.32 1
[Reference]
Female 149 6.28 1.35
(1.08-1.69)
216 5.21 0.94
(0.81-1.09)
274 5.15 0.91
(0.78-1.05)
347 5.36 0.84
(0.71-0.98)
54 5.45 1.21
(0.86-1.70)
Age at first
diagnosis, y
P = .07 P = .009 P = .24 P = .84 P = .39
15-49 75 4.83 1.13
(0.85-1.51)
363 5.90 1.26
(1.08-1.46)
197 5.61 1.17
(0.97-1.41)
229 5.72 1.06
(0.87-1.28)
47 5.39 1.33
(0.88-2.01)
50-64 148 5.71 1.31
(1.04-1.65)
376 5.52 1.11
(0.97-1.28)
240 5.24 1.08
(0.92-1.27)
208 5.46 1.01
(0.83-1.22)
52 4.94 1.18
(0.80-1.74)
≥65 242 5.07 1
[Reference]
357 5.16 1
[Reference]
302 5.35 1
[Reference]
217 5.74 1
[Reference]
44 3.90 1
[Reference]
Time between
diagnoses
P = .03 P < .001 P = .002 P = .06 P = .28
2 mo to <1 y 55 7.25 1.61
(1.14-2.28)
111 8.13 1.55
(1.26-1.92)
82 8.46 1.64
(1.27-2.12)
61 8.08 1.36
(1.02-1.82)
6 2.56 0.48
(0.21-1.11)
1 y to <5 y 172 5.53 1.21
(0.93-1.58)
360 5.83 1.13
(0.98-1.30)
230 5.27 1.10
(0.91-1.31)
210 6.14 1.05
(0.86-1.28)
36 4.27 0.80
(0.53-1.20)
5 y to <10 y 129 4.95 1.02
(0.78-1.34)
311 5.21 1.04
(0.90-1.20)
226 5.54 1.13
(0.95-1.35)
170 5.04 0.91
(0.74-1.11)
41 5.14 0.97
(0.66-1.41)
≥10 y 109 4.46 1
[Reference]
314 4.94 1
[Reference]
201 4.65 1
[Reference]
213 5.27 1
[Reference]
60 5.09 1
[Reference]
Site of
subsequent
primary invasive
melanomab
P < .001 P < .001 P < .001 P < .001 P = .15
Head 181 8.27 1
[Reference]
225 5.20 0.79
(0.68-0.93)
152 4.96 0.74
(0.60-0.91)
104 4.47 0.59
(0.46-0.76)
28 4.12 3.07
(0.93-10.1)
Trunk 149 4.84 0.56
(0.43-0.73)
520 6.83 1
[Reference]
254 5.55 0.80
(0.67-0.95)
212 5.98 0.76
(0.62-0.94)
60 5.64 4.08
(1.28-13.0)
Upper
extremities
111 4.56 0.52
(0.40-0.69)
329 6.33 0.95
(0.82-1.09)
255 6.75 1
[Reference]
197 6.05 0.81
(0.66-1.00)
41 4.95 3.50
(1.08-11.3)
Lower
extremities
63 3.61 0.38
(0.28-0.52)
188 4.96 0.73
(0.62-0.87)
164 5.40 0.80
(0.66-0.98)
215 7.27 1
[Reference]
31 4.85 3.25
(0.99-10.7)
Not specified 10 1.53 0.17
(0.09-0.34)
15 1.05 0.16
(0.09-0.26)
7 0.72 0.11
(0.05-0.23)
6 0.77 0.10
(0.05-0.23)
3 1.38 1
[Reference]
Abbreviations: Adj, adjusted; Obs, observed; SIR, standardized incidence ratio.
a P values represent the statistical significance of the overall effect for the
variable. Adjusted SIR ratios shown in boldface type are statistically significant
(P < .05).
bNumbers by site of subsequent primary invasive melanomasmay include
more than 1 per person.
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melanomas on the same part of the body, particularly the
head. This is consistent with the findings of Giles et al,7 who
reported a significant site concordance. They postulated
that this might signify a field effect because of the similar
sun exposure history of neighboring skin. Given that the
head is typically the most chronically sun-exposed part of
the body, our findings add further weight to this theory and
highlight the need for vigilant inspection around the site
where the first primary melanoma appeared.
Recently, the issue of subsequent primary melanomas
has become topical following improved survival for patients
with late-stage melanomas who received treatment with
vemurafenib.14 High frequencies of newly detected primary
melanomas within weeks of vemurafenib or other serine/
threonine protein kinase inhibitors being administered have
been described.15,16 Dalle et al17 and Haenssle et al18 have
stressed the importanceof repeated skinexamination, includ-
ing sequential dermoscopy, for the early detection of subse-
quent primary melanomas in patients who receive these
treatments.
Also of interest was our finding that the risk of a subse-
quent primary invasive melanoma following a first primary
in situ melanoma was more than 4 times higher than that in
the general population, and only slightly lower than the
relative risk following a first primary invasive melanoma.
Greater awareness and more widespread screening have
contributed to an overdiagnosis of melanoma in recent
years,19-21 as evidenced by increases in the incidence of in
situ and early-stage invasive tumors. Indeed, the higher
incidence of subsequent melanomas within the first year of
initial diagnosis may be explained, at least in part, by
heightened attention among patients with melanoma and
their physicians toward suspicious skin lesions. However,
the continuing elevated risk during the entire period of
Table 4. SIRs and Adj SIR Ratios for Subsequent Primary InvasiveMelanomas by Site of First Primary In SituMelanoma, Queensland, 1982-2010
Characteristica
Site of First Primary In Situ Melanoma
Head Trunk Upper Extremities Lower Extremities Not Specified
Obs SIR
Adj SIR
Ratio
(95% CI) Obs SIR
Adj SIR
Ratio
(95% CI) Obs SIR
Adj SIR
Ratio
(95% CI) Obs SIR
Adj SIR
Ratio
(95% CI) Obs SIR
Adj SIR
Ratio
(95% CI)
Sex P = .19 P = .34 P = .22 P = .16 P = .40
Male 328 3.82 1
[Reference]
392 4.97 1
[Reference]
225 4.58 1
[Reference]
90 4.75 1
[Reference]
32 4.32 1
[Reference]
Female 155 4.41 1.14
(0.94-1.38)
81 4.09 0.89
(0.70-1.13)
167 5.21 1.14
(0.93-1.40)
149 5.83 1.21
(0.93-1.56)
17 4.68 1.29
(0.72-2.32)
Age at first diag-
nosis, y
P = .24 P = .67 P = .17 P = .56 P = .49
15-49 60 4.35 1.25
(0.95-1.65)
106 4.74 0.96
(0.76-1.22)
92 5.83 1.20
(0.93-1.56)
79 5.32 1.06
(0.77-1.45)
11 3.82 0.81
(0.37-1.77)
50-64 155 4.05 1.11
(0.91-1.34)
171 4.66 0.91
(0.75-1.11)
127 4.47 0.93
(0.75-1.17)
89 5.63 1.17
(0.87-1.57)
21 5.22 1.25
(0.67-2.31)
≥65 268 3.88 1
[Reference]
196 4.96 1
[Reference]
173 4.68 1
[Reference]
71 5.12 1
[Reference]
17 4.11 1
[Reference]
Time between
diagnoses
P = .38 P = .20 P = .59 P = .33 P = .41
2 mo to <1 y 38 4.14 1.00
(0.70-1.43)
44 6.18 1.06
(0.76-1.49)
33 5.55 1.11
(0.75-1.64)
24 8.33 1.54
(0.97-2.43)
3 5.58 1.39
(0.40-4.82)
1 y to <5 y 158 3.74 0.90
(0.72-1.13)
169 4.95 0.89
(0.72-1.11)
127 4.51 0.90
(0.69-1.16)
77 5.53 1.05
(0.77-1.44)
14 5.44 1.51
(0.74-3.06)
5 y to <10 y 164 4.38 1.10
(0.88-1.36)
133 4.18 0.81
(0.65-1.01)
130 4.96 1.03
(0.80-1.32)
68 4.88 1.08
(0.79-1.47)
16 5.42 1.74
(0.90-3.36)
≥10 y 123 3.82 1
[Reference]
127 4.97 1
[Reference]
102 4.90 1
[Reference]
70 5.08 1
[Reference]
16 3.22 1
[Reference]
Site of
subsequent
primary invasive
melanomab
P = .001 P < .001 P = .005 P = .41 P = .71
Head 156 5.18 1
[Reference]
81 3.65 0.60
(0.46-0.78)
69 3.76 0.67
(0.50-0.91)
39 4.54 0.80
(0.54-1.20)
8 3.11 0.50
(0.16-1.58)
Trunk 142 3.52 0.67
(0.53-0.85)
223 6.02 1
[Reference]
140 5.31 0.95
(0.74-1.21)
79 5.83 1.03
(0.74-1.44)
20 5.36 0.83
(0.30-2.33)
Upper
extremities
118 3.55 0.67
(0.53-0.85)
137 5.27 0.88
(0.71-1.09)
128 5.73 1
[Reference]
73 5.87 1.00
(0.72-1.40)
14 4.56 0.69
(0.24-2.00)
Lower
extremities
82 3.43 0.63
(0.48-0.82)
71 3.84 0.65
(0.50-0.86)
76 4.26 0.72
(0.54-0.96)
69 6.02 1
[Reference]
14 6.02 0.88
(0.30-2.57)
Not specified 36 4.09 0.78
(0.54-1.12)
32 4.50 0.75
(0.52-1.08)
16 2.81 0.50
(0.30-0.84)
10 2.90 0.60
(0.31-1.17)
5 6.32 1
[Reference]
Abbreviations: Adj, adjusted; Obs, observed; SIR, standardized incidence ratio.
a P values represent the statistical significance of the overall effect for the
variable. Adjusted SIR ratios shown in boldface type are statistically significant
(P < .05).
bNumbers by site of subsequent primary invasive melanomasmay include
more than 1 per person.
Distribution of Invasive Melanoma in Australia Original Investigation Research
jamadermatology.com JAMADermatology May 2014 Volume 150, Number 5 531
Downloaded From: https://archderm.jamanetwork.com/ by Rory  Jackson on 10/12/2015
Copyright 2014 American Medical Association. All rights reserved.
follow-up clearly suggests that people with an in situ or
invasive melanoma share an inherently higher melanoma
risk than the general population.
Although the value of follow-up for patients with later-
stage melanoma is unequivocal, the same level of consensus
has not been evident for those with very thin or in situ
melanoma.22 The findings of the present study place patients
with insitumelanomainahigh-riskcategoryandprovidestrong
grounds for continuingclinical follow-upandeducationwithin
this group. To date, no randomized clinical trials have evalu-
ated follow-up intervals or lengthof the follow-upperiod;nev-
ertheless, most guidelines recommend more frequent fol-
low-up for later-stage melanomas in the first 5 years and
annually thereafter. However, there is little consistency in re-
lation to follow-upfor insitumelanoma.23-25The findings in the
present studymay indicate theneed forpatientswith in situor
early-stagemelanoma to bemonitoredmore closely for a pro-
longed period. Furthermore, it is well recognized in Australia
that patients aremore likely than physicians to initially detect
aprimarymelanoma26ora recurrence.27However, it seemsthat
patients are less likely than physicians to detect a second pri-
mary melanoma.28,29 Current Australian clinical practice
guidelines23 recommend that teaching skin self-examination
should be a high priority in follow-up care for people with in-
vasive melanoma; our results suggest that this should be ex-
tended to include those with an in situmelanoma.
Itwouldseemreasonable tosuggest thatsurvivalwouldde-
creasewith a greater number of primary invasivemelanomas,
but studies30,31 examining theeffect ofmultipleprimarymela-
nomas on survival have not supported this view. A recent re-
port from the Genes, Environment, and Melanoma Study30
found no significant difference in prognosis between patients
with single vs multiple primary invasive melanomas after ad-
justing for other factors.Anearlier study31 even reporteda sur-
vival advantage for patients with 3 or more invasive melano-
mas compared with patients with a single melanoma; the
authors speculated that this may be akin to an immunization
effect. No literature is available on studies that assessed other
possible consequencesof thediagnosis of subsequentprimary
melanomas, such as the effect on quality of life for survivors.
One of the main strengths of the present study is the full
population-basedcoverageofmelanomacasescollectedby the
QueenslandCancerRegistry. Therewas also ahigh level of his-
topathologic verification (99% in 2009 and 2010),3 which en-
abled us to distinguish between new primarymelanomas and
metastasesof anexistingmelanoma.Given thegreatly increas-
ing incidenceof in situmelanomaduring the studyperiod,2we
wereunable todistinguishwhether this is a real increaseor the
Figure. Standardized Incidence Ratios (SIRs) for Subsequent Primary InvasiveMelanomas by Site, Behavior of First PrimaryMelanoma, and
Sex—Queensland, 1982-2010
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resultofunmeasuredchanges inclinicalpractice. Itcouldbethat
there is sometemporalheterogeneity in thecompositionof the
in situ lesions; however, this would not explain the increased
risk of subsequent invasivemelanomas among this group.
The risks reported here are relative to those of the gen-
eral population, and so do not represent the absolute risks of
subsequent melanomas among the cohort. This is an impor-
tantdistinctionandhas implications for thecomparisonof sub-
groups. Similar to other investigations,32-34 our study found
that, compared with the general population, younger people
had a higher relative risk of subsequent melanoma than did
older people. However, it also has been shown9 that the abso-
lute risk is higher among older people, and this needs to be
borne in mind when interpreting our results.
Although most patients in the present study with mul-
tiple lesionsdevelopedonly1additionalprimary invasivemela-
noma, 11%developed2ormoreatdifferentbodysites.Thepos-
sibility that this latter groupmayhaveageneticpredisposition
cannot be excluded. It has been estimated35 that approxi-
mately 10% of patients with melanoma have a family history
of the disease.
The overall SIR presented for subsequent primary inva-
sive melanomas was somewhat lower than the result re-
ported in an earlier article6 that considered all second pri-
mary cancers in Queensland. This was because of minor
methodologic differences. In the first study, follow-up was
truncatedwhen any type of second primary cancer was diag-
nosed. Cancers other thanmelanomawere not considered in
the present study; consequently, many melanoma survivors
would have the potential for a longer follow-up time, which
would in turn increase theexpectednumberofmelanomasand
hence lower the SIR.
Conclusions
Toourknowledge,wehavequantified for the first timetherela-
tive risks by body site of a subsequent primary invasivemela-
noma being diagnosed in peoplewith a first primary invasive
or in situmelanoma. The relative riskswere generally highest
for the samebody site, although thevariationobservedbykey
patientandtumorcharacteristicsemphasizes that certaincom-
binationsofsitesanddemographicattributes requiremorevigi-
lant follow-up.These findingshave important implications for
thedual spheresofpublichealthandclinicalpracticeandhigh-
light that education and continued surveillance are para-
mount not only for persons with invasivemelanoma but also
for those with an in situ melanoma.
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NOTABLENOTES
Doctor, Your Next Patient Is the Rabbit in Room7
Walter H. C. Burgdorf, MD
Oneof theUSprivatepractitionerswhomade inestimable researchcon-
tributionswasVinceBarranco (1937-2013) fromTulsa,Oklahoma.Vince
wasborn inGranada,Mississippi, and trained indermatologyunderMark
Allen Everett at the University of Oklahoma. In 1969 he joined Dwane
Minor and Kendrick Doran at the Tulsa Dermatology Clinic.
Vince became fascinated by dapsone during his residency and de-
cided to investigate its method of action. The clinic was in a new build-
ing thatwasdesignedwith foresight to accommodate4physicianswith
4 suites of examining rooms radiating out from a central nursing area.
One wing was free; it became Vince’s laboratory. He acquired 28 rab-
bits and injected themwith large doses of vitamin A daily, inducing up-
regulation of lysosomal enzymes, damage to chondroitin sulfate, and
floppy ears. Vince set up a classic study: 8 rabbits received vitamin A
alone;8, vitamin Aplus methylprednisolone; and8, vitaminAplusdap-
sone; and 4 served as controls. The distal ear tips collapsed in the rab-
bits treated with vitamin A alone by day 5; systemic signs of toxic ef-
fects and hair loss appeared by day 8. Both dapsone and
methylprednisolone blocked the ear changes and reduced hair loss, al-
though systemic toxic effects were not influenced.
The cartilage from the trachea and femoral headwas studied histo-
logically because previous studies had shown evaluating the ear carti-
lagewasunreliable.Thetracheal cartilagewasthinnedandstainedpoorly
with toluidine blue in the rabbits treated only with vitamin A; in addi-
tion, thearticular cartilagewas reduced in thicknessby two-thirds.Both
dapsone andmethylprednisolone prevented these changes.1
Vince was featured in one of Berton Roueché’s2 medical detective
articles inTheNewYorker. InAntipathies, published inMarch 1978,Roue-
chédiscussedapatientofVince’s,whodevelopedasystemicallergiccon-
tact dermatitis triggered by an intrauterine contraception device con-
taining copper. This article andVince’swork,which hadbeenpublished
6yearsearlier,3werealmost thebeginningof implant immunologystud-
ies,which acquired great relevance as physicians starting implanting all
sorts of metals in many different body sites.
Vince was not only a creative, office-based researcher; he was also
a consummate and caring clinicianwhose opinionwas regularly sought
ondifficult cases anywherewithin rangeof Tulsa.We should all remem-
ber him as a classic example of what can be accomplished in a private
office by a curious clinician.
PS:When I shared thisNotableNotewithmy frequent collaborator,
DavidBickers, he toldme thathis father,WilliamM.Bickers, a gynecolo-
gist in Richmond, Virginia, had rabbits in his office in the 1950s, while
he was looking for a drug to prevent or treat menstrual cramps.
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